MX2009004438A - Uso de inhibidores cinasa de objetivos multiples 1 para tratar o prevenir cancer de hueso. - Google Patents

Uso de inhibidores cinasa de objetivos multiples 1 para tratar o prevenir cancer de hueso.

Info

Publication number
MX2009004438A
MX2009004438A MX2009004438A MX2009004438A MX2009004438A MX 2009004438 A MX2009004438 A MX 2009004438A MX 2009004438 A MX2009004438 A MX 2009004438A MX 2009004438 A MX2009004438 A MX 2009004438A MX 2009004438 A MX2009004438 A MX 2009004438A
Authority
MX
Mexico
Prior art keywords
bone
treating
preventing
bone cancer
cancer
Prior art date
Application number
MX2009004438A
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Timothy Pietro Suren Perera
Theo Frans Meert
Michel Marie Francois Janicot
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2009004438A publication Critical patent/MX2009004438A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención está relacionada con el descubrimiento de que el derivado quinazolina macrocíclico 4,6-etanodiilidenpirimido [4,5-b][6,1,12]benzoxadiazaciclo-pentadecina, 17-bromo-8,9,10,11,12,13,14,19-octahidro-20-metoxi-13-metilo, descrito como compuesto 22 en la publicación PCT WO2004/105765, es útil en la elaboración de un medicamento para el tratamiento o prevención de cánceres de hueso y métodos para eliminar células de cáncer de hueso, incluyendo osteosarcomas, condrosarcomas, enfermedad de mieloma de hueso y metástasis de hueso osteolítico derivadas de otros sitios primarios; en consecuencia, la invención provee métodos para tratar, prevenir, demorar o mitigar el cáncer de hueso, o para prevenir o tratar pérdida de hueso asociada con metástasis de cáncer.
MX2009004438A 2006-10-27 2007-10-25 Uso de inhibidores cinasa de objetivos multiples 1 para tratar o prevenir cancer de hueso. MX2009004438A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86316706P 2006-10-27 2006-10-27
EP06123060 2006-10-27
US97618807P 2007-09-28 2007-09-28
PCT/EP2007/061501 WO2008049904A2 (en) 2006-10-27 2007-10-25 Use of mtki 1 for treating or preventing bone cancer

Publications (1)

Publication Number Publication Date
MX2009004438A true MX2009004438A (es) 2009-05-11

Family

ID=39066650

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004438A MX2009004438A (es) 2006-10-27 2007-10-25 Uso de inhibidores cinasa de objetivos multiples 1 para tratar o prevenir cancer de hueso.

Country Status (11)

Country Link
EP (1) EP2101782A2 (es)
JP (1) JP2010507628A (es)
KR (1) KR20090086977A (es)
AU (1) AU2007310845A1 (es)
BR (1) BRPI0718021A2 (es)
CA (1) CA2664165A1 (es)
EA (1) EA200970420A1 (es)
IL (1) IL198344A0 (es)
MX (1) MX2009004438A (es)
NO (1) NO20092059L (es)
WO (1) WO2008049904A2 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
GB0507347D0 (en) * 2005-04-12 2005-05-18 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
WO2008049904A3 (en) 2009-01-15
KR20090086977A (ko) 2009-08-14
IL198344A0 (en) 2010-02-17
EP2101782A2 (en) 2009-09-23
BRPI0718021A2 (pt) 2013-11-12
CA2664165A1 (en) 2008-05-02
AU2007310845A1 (en) 2008-05-02
JP2010507628A (ja) 2010-03-11
WO2008049904A2 (en) 2008-05-02
EA200970420A1 (ru) 2009-12-30
NO20092059L (no) 2009-06-29

Similar Documents

Publication Publication Date Title
MX2009006627A (es) Quinazolinas para la inhibicion de pdk1.
MX2008012852A (es) Quinazolinas para la inhibicion de pdk1.
MX2009008510A (es) Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer.
IN2014KN02886A (es)
SI2054418T1 (sl) Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji
UA99597C2 (ru) Пиримидилциклопентаны как ингибиторы акт протеинкиназ
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
TN2011000298A1 (en) Compounds useful for inhibiting chk1
WO2007053573A3 (en) Treatment of cancer with sorafenib
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
WO2007098507A3 (en) Compositions and methods for inhibition of the jak pathway
TW200716141A (en) Compositions and methods for treatment for neoplasms
WO2007087245A3 (en) Ret tyrosine kinase inhibition
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
TW200801008A (en) Protein kinase inhibitors
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
NZ590550A (en) Inhibitors of Apoptosis (IAP) for treating cancer
WO2010048026A3 (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
UA96265C2 (ru) Композиция и способ ингибирования jak пути передачи сигнала
WO2004075775A3 (en) Treatment of excessive osteolyisis with indolinone compounds
TW200719903A (en) Compositions for the treatment of neoplasms
MX2009004438A (es) Uso de inhibidores cinasa de objetivos multiples 1 para tratar o prevenir cancer de hueso.